Efavirenz and the CNS: what we already know and questions that need to be answered (Q28085028)

Haryes A. Funes

2

1 reference

Ana Blas-Garcia

3

1 reference

Maria J. Galindo

4

1 reference

Angeles Alvarez

5

1 reference

Juan V. Esplugues

6

1 reference

language of work or name

1 reference

October 2015

1 reference

Journal of Antimicrobial Chemotherapy

published in

1 reference

volume

70

1 reference

issue

10

1 reference

page(s)

2693-708

1 reference

Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

NNRTIs: pharmacological data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

CYP2B6 (c.516G→T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Efavirenz dose reduction is safe in patients with high plasma concentrations and may prevent efavirenz discontinuations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Higher efavirenz plasma levels correlate with development of insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Efavirenz-induced catatonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Psychosis in a 12-year-old HIV-positive girl with an increased serum concentration of efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Efavirenz intoxication due to slow hepatic metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Association of high T allele frequency of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plasma efavirenz and nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Antiretroviral neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease?.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Efavirenz concentrations in CSF exceed IC50 for wild-type HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Protein-free efavirenz concentrations in cerebrospinal fluid and blood plasma are equivalent: applying the law of mass action to predict protein-free drug concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

CSF penetration by antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Editorial commentary: cerebrospinal fluid inhibitory quotients of antiretroviral drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Periconceptional exposure to efavirenz and neural tube defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Myelomeningocele in a child with intrauterine exposure to efavirenz.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Antiretroviral therapy for previously untreated HIV-1-infected adults: 2NN, or just one?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Adverse drug reactions to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimen: a 24-week prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Central nervous system adverse effects with efavirenz: case report and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

A systematic review of the psychiatric side-effects of efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Recreational substance use and tolerance of efavirenz in HIV-1 infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Central nervous system disorders after starting antiretroviral therapy in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Recurrence of post-traumatic stress disorder symptoms after initiation of antiretrovirals including efavirenz: a report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Recurrence of post-traumatic stress disorder and antiretrovirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Antiretroviral therapy reduces neurodegeneration in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Tolerance of efavirenz-induced central nervous system side effects in HIV-infected individuals with a history of substance abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Effect of treatment with efavirenz on neuropsychiatric adverse events of interferon in HIV/HCV-coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Anti-HIV drugs nevirapine and efavirenz affect anxiety-related behavior and cognitive performance in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Efavirenz induces depressive-like behaviour, increased stress response and changes in the immune response in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Implications of efavirenz for neuropsychiatry: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

The HIV antiretroviral drug efavirenz has LSD-like properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Efavirenz promotes β-secretase expression and increased Aβ1-40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Effects of the HIV treatment drugs nevirapine and efavirenz on brain creatine kinase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Creatine kinase B-driven energy transfer in the brain is important for habituation and spatial learning behaviour, mossy fibre field size and determination of seizure susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Reduced creatine kinase activity in transgenic amyotrophic lateral sclerosis mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Oxidative modification of creatine kinase BB in Alzheimer's disease brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Neuronal bioenergetics and acute mitochondrial dysfunction: a clue to understanding the central nervous system side effects of efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Enhanced oxidative stress and increased mitochondrial mass during efavirenz-induced apoptosis in human hepatic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Nitric oxide switches on glycolysis through the AMP protein kinase and 6-phosphofructo-2-kinase pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Glycolysis: a bioenergetic or a survival pathway?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

The antiretroviral protease inhibitors indinavir and nelfinavir stimulate Mrp1-mediated GSH export from cultured brain astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

8-Hydroxy-efavirenz, the primary metabolite of the antiretroviral drug Efavirenz, stimulates the glycolytic flux in cultured rat astrocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Differential regulation of Mn-superoxide dismutase in neurons and astroglia by HIV-1 gp120: Implications for HIV-associated dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Antiretroviral agents increase NO production in gp120/IFNγ-stimulated cultures of rat microglia via an arginase-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Involvement of nitric oxide in the mitochondrial action of efavirenz: a differential effect on neurons and glial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Pharmacokinetics of plasma efavirenz and CYP2B6 polymorphism in southern Chinese.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 resul

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Mitochondrial interference by anti-HIV drugs: mechanisms beyond Pol-γ inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 w

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

Preliminary Data of a Prospective Study on Neuropsychiatric Side Effects After Initiation of Efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV183

21 January 2018

Identifiers

DOI

10.1093/JAC/DKV183

0 references

PubMed publication ID

26203180

1 reference